» Articles » PMID: 19342466

The Calibration of Treatment Effects from Clinical Trials to Target Populations

Overview
Journal Clin Trials
Publisher Sage Publications
Date 2009 Apr 4
PMID 19342466
Citations 29
Authors
Affiliations
Soon will be listed here.
Citing Articles

Visualizing External Validity: Graphical Displays to Inform the Extension of Treatment Effects from Trials to Clinical Practice.

Lund J, Webster-Clark M, Westreich D, Sanoff H, Robert N, Frytak J Epidemiology. 2024; 35(2):241-251.

PMID: 38290143 PMC: 10826920. DOI: 10.1097/EDE.0000000000001694.


Causal isotonic calibration for heterogeneous treatment effects.

van der Laan L, Ulloa-Perez E, Carone M, Luedtke A Proc Mach Learn Res. 2023; 202:34831-34854.

PMID: 37575467 PMC: 10416780.


Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia.

Basu A, Patel C, Fu A, Brown B, Mavros P, Benson C J Manag Care Spec Pharm. 2023; 29(3):293-302.

PMID: 36692909 PMC: 10394194. DOI: 10.18553/jmcp.2023.22191.


Universal adaptability: Target-independent inference that competes with propensity scoring.

Kim M, Kern C, Goldwasser S, Kreuter F, Reingold O Proc Natl Acad Sci U S A. 2022; 119(4).

PMID: 35046023 PMC: 8794832. DOI: 10.1073/pnas.2108097119.


A comparison of reweighting estimators of average treatment effects in real world populations.

Lin C, Kaizar E, Faries D, Johnston J Pharm Stat. 2021; 20(4):765-782.

PMID: 33675139 PMC: 8359356. DOI: 10.1002/pst.2106.


References
1.
Frangakis C, Rubin D . Principal stratification in causal inference. Biometrics. 2002; 58(1):21-9. PMC: 4137767. DOI: 10.1111/j.0006-341x.2002.00021.x. View

2.
Hernan M, Alonso A, Logan R, Grodstein F, Michels K, Willett W . Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008; 19(6):766-79. PMC: 3731075. DOI: 10.1097/EDE.0b013e3181875e61. View

3.
Weisberg H, Hayden V, Pontes V . Selection criteria and generalizability within the counterfactual framework: explaining the paradox of antidepressant-induced suicidality?. Clin Trials. 2009; 6(2):109-18. DOI: 10.1177/1740774509102563. View

4.
Fleming T, DeMets D . Surrogate end points in clinical trials: are we being misled?. Ann Intern Med. 1996; 125(7):605-13. DOI: 10.7326/0003-4819-125-7-199610010-00011. View